RayKnowChina Research Map
Shortlist

Xi'anAir Force Medical University

Tangdu Hospital

空军军医大学唐都医院

Listed for 16 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Tangdu Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌13 papers led7 open trials led
  2. Hepatocellular carcinoma肝细胞癌16 papers led
  3. Stomach cancer胃癌9 papers led1 open trial led
  4. Hepatoblastoma肝母细胞瘤1 paper led
  5. Retinoblastoma视网膜母细胞瘤1 paper led
  6. Osteosarcoma骨肉瘤3 papers led
  7. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  8. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病5 papers led3 open trials led
  9. Myasthenia gravis重症肌无力19 papers led3 open trials led
  10. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
  11. Takayasu arteritis大动脉炎0 papers led
  12. Hepatic echinococcosis肝包虫病0 papers led
  13. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  14. IgA nephropathyIgA 肾病0 papers led
  15. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  16. Hirschsprung disease先天性巨结肠0 papers led

Not listed for: Nasopharyngeal carcinoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 13 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
13
2021–2025
Trials led
8
any status, ClinicalTrials.gov
Open trials led
7
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 4420222023: 3320232024: 2220242025: 442025

5 hospitals in Xi'an for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07385001

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  2. Recruiting
    Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07452601

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  3. Recruiting
    Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06663059

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  4. Recruiting
    Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
    Phase
    Phase 2
    Started
    2022-08
    Registry
    NCT06006650

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  5. Not yet recruiting
    Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT06952621

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  6. Not yet recruiting
    Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07618910

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  7. Not yet recruiting
    Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07678580

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentImmunotherapyMolecular markers & genomics
Departments in papersGastroenterology / hepatologyPathology / laboratory medicineRadiation oncology
Papers it led13
  1. Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma.2025BMC cancerFree full text
  2. Development and validation of a novel signature to predict the survival and affect the immune microenvironment of esophageal squamous cell carcinoma: epigenetic-related genes.2025Frontiers in immunologyFree full text
  3. Effect of immune infiltration intensity on the efficacy of neoadjuvant immunotherapy for esophageal cancer.2025Frontiers in immunologyFree full text
  4. Relaxin 2 Suppresses Tumor Growth in Esophageal Squamous Cell Carcinoma EC9706 Cells Through Modulation of the STAT Signaling Pathway.2025Journal of biochemical and molecular toxicology
  5. CircGFPT1 regulates the growth and apoptosis of esophageal squamous cell carcinoma through miR-142-5p/HAX1 axis.2024General thoracic and cardiovascular surgery
  6. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.2024Genome medicineFree full text
  7. Identification of the pyroptosis-related gene signature and risk score model for esophageal squamous cell carcinoma.2023AgingFree full text
  8. JMJD6 functions as an oncogene and is associated with poor prognosis in esophageal squamous cell carcinoma.2023BMC cancerFree full text
  9. Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer.2023BMC gastroenterologyFree full text
  10. WNT5A promotes the metastasis of esophageal squamous cell carcinoma by activating the HDAC7/SNAIL signaling pathway.2022Cell death & diseaseFree full text
  11. Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE).2022Frontiers in immunologyFree full text
  12. Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.2022Frontiers in immunologyFree full text
  13. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE).2022International journal of surgery (London, England)
All its trials on ClinicalTrials.gov, any status10
  1. A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCCRecruitingNCT07385001Lead sponsorPhase 1/Phase 2Start 2026-01
  2. Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06952621Lead sponsorPhase 3Start 2026-02
  3. Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCCRecruitingNCT07452601Lead sponsorPhase 2Start 2026-05
  4. Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCCNot yet recruitingNCT07618910Lead sponsorPhase 2Start 2026-05
  5. Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07678580Lead sponsorPhase 2Start 2026-07
  6. Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles StudyRecruitingNCT06663059Lead sponsorPhase 2Start 2024-10
  7. Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous CellRecruitingNCT06006650Lead sponsorPhase 2Start 2022-08
  8. Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCCStatus unknownNCT06475196Lead sponsorStart 2024-06
  9. Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell CarcinomaCompletedNCT04974047Study sitePhase 2Start 2021-08
  10. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
More papers found outside PubMed (not counted)7
  1. Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis2025Journal of Clinical Oncologyconference-abstract
  2. Envafolimab plus chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study.2024Journal of Clinical Oncologyconference-abstract
  3. Exploration on the Effects and Molecular Mechanisms of Pterostilbene on Esophageal Cancer Based on Network Pharmacology2024Journal of Contemporary Medical Practicearticle
  4. 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)2023Annals of Oncologyarticle
  5. Effect of system analysis of reactive oxygen species on prognosis and treatment decisions for patients with esophageal squamous carcinoma.2023Journal of Clinical Oncologyconference-abstract
  6. Elevated Serum CA724 Induced by Chemotherapy in Patients with Esophageal Squamous Cell Carcinoma2022Research Squarepreprint
  7. 144P Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer (TD-NICE): A single arm, phase II study2021Annals of Oncologyarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 16 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
16
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 5520222023: 3320232024: 0020242025: 552025

4 hospitals in Xi'an for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesHepatitis B & cirrhosisImaging, AI & early detectionRecurrence & prognosis
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led16
  1. Diagnostic Values of Magnetic Resonance Imaging and Computed Tomography for Predicting Macrotrabecular-Massive Hepatocellular Carcinoma Subtype: A Meta-analysis.2025Academic radiology
  2. Exosomal Pparα derived from cancer cells induces CD8 + T cell exhaustion in hepatocellular carcinoma through the miR-27b-3p /TOX axis.2025Chinese medical journalFree full text
  3. Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma.2025Clinical and molecular hepatologyFree full text
  4. Pegylated Interferon-α-Induced Functional Cure for Special Populations with Chronic Hepatitis B Virus Infection: Current Trends, Challenges and Prospection.2025Drug design, development and therapyFree full text
  5. Multiple features of cell-free mtDNA for predicting transarterial chemoembolization response in hepatocellular carcinoma.2025Hepatology communicationsFree full text
  6. Role of CD5 molecular-like on hepatocellular carcinoma.2023Chinese medical journalFree full text
  7. Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.2023Clinical journal of gastroenterology
  8. OCTN2 enhances PGC-1α-mediated fatty acid oxidation and OXPHOS to support stemness in hepatocellular carcinoma.2023Metabolism: clinical and experimental
  9. Mechanism of cancer stemness maintenance in human liver cancer.2022Cell death & diseaseFree full text
  10. HCV Core protein represses DKK3 expression via epigenetic silencing and activates the Wnt/β-catenin signaling pathway during the progression of HCC.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  11. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.2022Experimental cell research
  12. Down-regulation of BMAL1 by MiR-494-3p Promotes Hepatocellular Carcinoma Growth and Metastasis by Increasing GPAM-mediated Lipid Biosynthesis.2022International journal of biological sciencesFree full text
  13. Acyl-CoA thioesterase 9 promotes tumour growth and metastasis through reprogramming of fatty acid metabolism in hepatocellular carcinoma.2022Liver international : official journal of the International Association for the Study of the Liver
  14. Down-regulation of SLC25A20 promotes hepatocellular carcinoma growth and metastasis through suppression of fatty-acid oxidation.2021Cell death & diseaseFree full text
  15. Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling.2021Molecular cancerFree full text
  16. Characterization of fragment sizes, copy number aberrations and 4-mer end motifs in cell-free DNA of hepatocellular carcinoma for enhanced liquid biopsy-based cancer detection.2021Molecular oncologyFree full text
All its trials on ClinicalTrials.gov, any status7
  1. Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver FunctionCompletedNCT06245785Lead sponsorStart 2023-01
  2. Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal HypertensionCompletedNCT06245798Lead sponsorStart 2023-01
  3. Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib TreatmentStatus unknownNCT05113290Study sitePhase 4Start 2021-12
  4. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  5. Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery RecurrenceStatus unknownNCT04213118Study sitePhase 2Start 2020-04
  6. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) SubjectsTerminatedNCT03591965Study sitePhase 2Start 2018-08
  7. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCCompletedNCT03516071Study sitePhase 2Start 2017-05

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 9 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.09%.

Papers led
9
2021–2025
Trials led
7
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 2220242025: 222025

7 hospitals in Xi'an for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2024-09
    Registry
    NCT06128252

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an

  2. Recruiting
    Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer
    Phase
    Not given
    Started
    2025-05
    Registry
    NCT06979895

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 1 listed hospital as study siteXi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImmunotherapy & targeted drugsSurgery
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyGastroenterology / hepatologyRadiology / nuclear medicine
Papers it led9
  1. Phase II study of perioperative camrelizumab and XELOX for locally advanced gastric or gastroesophageal junction adenocarcinoma.2025Cancer scienceFree full text
  2. SLC25A42 promotes gastric cancer growth by conferring ferroptosis resistance through enhancing CPT2-mediated fatty acid oxidation.2025Cell death & diseaseFree full text
  3. Association of PD-L1 Expression with Clinicopathologic Characters in Gastric Cancer: A Comprehensive Meta-analysis.2024Current medicinal chemistry
  4. DBH-YOLO: a surgical instrument detection method based on feature separation in laparoscopic surgery.2024International journal of computer assisted radiology and surgery
  5. Development a m6A regulators characterized by the immune cell infiltration in stomach adenocarcinoma for predicting the prognosis and immunotherapy response.2023AgingFree full text
  6. Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.2023Journal of translational medicineFree full text
  7. Rho GTPase-activating protein 35 suppresses gastric cancer metastasis by regulating cytoskeleton reorganization and epithelial-to-mesenchymal transition.2022BioengineeredFree full text
  8. A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-III gastric cancer.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia GroupRCT
  9. Long non-coding RNA Down syndrome cell adhesion molecule-anti-sense 1 promotes gastric carcinoma cell proliferation and migration by regulating the miR-204/TPT1 axis.2021Human & experimental toxicology
Chinese-language papers (not in the count)1
  1. [Propensity score matching analysis of the short-term efficacy of Kamikawa versus double- tract reconstruction in laparoscopic proximal gastric cancer surgery].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status21
  1. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric CancerRecruitingNCT06128252Lead sponsorN/AStart 2024-09
  2. Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric CancerStatus unknownNCT06475417Lead sponsorPhase 2Start 2024-05
  3. Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric CancerStatus unknownNCT06123455Lead sponsorPhase 2Start 2023-08
  4. New Adjuvant Treatment of Locally Advanced Resectable Gastric Cancer With Carelizumab and XELOXStatus unknownNCT05715632Lead sponsorN/AStart 2023-02
  5. SP Intravenous Chemotherapy Versus SP by HIPEC in Stage Ⅲ Patients After D2 GastrectomyStatus unknownNCT02396498Lead sponsorPhase 3Start 2014-04
  6. S-1 Combined Cisplatin HIPEC for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal MetastasisStatus unknownNCT02291211Lead sponsorPhase 2Start 2014-09
  7. Evaluation of Four Reconstructions After Total GastrectomyStatus unknownNCT00677456Lead sponsorPhase 1Start 2008-01
  8. Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric CancerRecruitingNCT06979895Study siteStart 2025-05
  9. Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric JunctionActive, not recruitingNCT06576921Study sitePhase 2Start 2024-11
  10. Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA SequencingStatus unknownNCT06036563Study siteStart 2023-09
  11. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  12. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  13. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Study sitePhase 3Start 2020-07
  14. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Study sitePhase 2/Phase 3Start 2019-12
  15. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric CancersStatus unknownNCT03468712Study siteN/AStart 2018-03
  16. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Study sitePhase 3Start 2017-03
  17. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02
  18. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  19. Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total GastrectomyStatus unknownNCT02110628Study sitePhase 3Start 2014-08
  20. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04
  21. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)Status unknownNCT01609309Study sitePhase 3Start 2012-09

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

5 hospitals in Xi'an for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

12 hospitals in Xi'an for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

27 hospitals in Xi'an for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led3
  1. LINC00673 promotes osteosarcoma progression through the miR-92b-3p/DUSP1 axis.2025Pathology, research and practice
  2. EYA4 reduces chemosensitivity of osteosarcoma to doxorubicin through DNA damage repair.2024Biochemical pharmacology
  3. Tandem mass tag (TMT) quantitative protein analysis-based proteomics and parallel reaction monitoring (PRM) validation revealed that MST4 accelerates osteosarcoma proliferation by increasing MRC2 activity.2023Molecular carcinogenesis
Earlier papers (2016–2020)8
  1. Extracellular vesicle-mediated delivery of miR-101 inhibits lung metastasis in osteosarcoma.2020Theranostics
  2. LAIR-1 overexpression inhibits epithelial-mesenchymal transition in osteosarcoma via GLUT1-related energy metabolism.2020World journal of surgical oncology
  3. Self-seeding circulating tumor cells promote the proliferation and metastasis of human osteosarcoma by upregulating interleukin-8.2019Cell death & disease
  4. Downregulation of the long non‑coding RNA FOXD2‑AS1 inhibits cell proliferation, migration and invasion in osteosarcoma.2019Molecular medicine reports
  5. Hypoxia promotes chemotherapy resistance by down-regulating SKA1 gene expression in human osteosarcoma.2017Cancer biology & therapy
  6. Interleukin-6 suppression reduces tumour self-seeding by circulating tumour cells in a human osteosarcoma nude mouse model.2016Oncotarget
  7. [CCR7 silence by siRNA inhibits proliferation, invasion and promotes apoptosis of human MG63 osteosarcoma cells].2016Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  8. [miR-365 inhibits proliferation and promotes apoptosis of SOSP9607 osteosarcoma cells].2016Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Xi'an for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEBV & infection triggersDiagnosis & prognosis

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 5 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.0%.

Papers led
5
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025

1 hospital in Xi'an for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07377305

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  2. Recruiting
    Ofatumumab in AQP4-IgG Seropositive NMOSD
    Phase
    Phase 1/Phase 2
    Started
    2022-06
    Registry
    NCT05504694

    Age 18 years to Not stated (registered criteria)

    Led by Tangdu HospitalXi'an

  3. Not yet recruiting
    Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
    Phase
    Phase 4
    Started
    2026-06
    Registry
    NCT07699770

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changchun, Chongqing, Kunming, Shenyang, Xi'an

  4. Recruiting
    Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
    Phase
    Early phase 1
    Started
    2022-04
    Registry
    NCT05145361

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Taiyuan, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBiologic drugsAntibodies & diagnosisRelapse prevention
Departments in papersNeurology
Papers it led5
  1. Long-term efficacy and safety of low-dose rituximab strategy in neuromyelitis optica spectrum disorder: a retrospective cohort study on treatment compliance and clinical outcomes.2025Orphanet journal of rare diseasesFree full text
  2. The levels of circulating cytokines and risk of neuromyelitis optica spectrum disorder: a Mendelian randomization study.2024Frontiers in immunologyFree full text
  3. CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder.2024Journal of neuroinflammationFree full text
  4. Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study.2023Frontiers in immunologyFree full text
  5. Emerging trends and research foci of neuromyelitis optica spectrum disorder: a 20-year bibliometric analysis.2023Frontiers in immunologyFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory TrialNot yet recruitingNCT07699770Lead sponsorPhase 4Start 2026-06
  2. Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)RecruitingNCT07377305Lead sponsorN/AStart 2025-12
  3. Ofatumumab in AQP4-IgG Seropositive NMOSDRecruitingNCT05504694Lead sponsorPhase 1/Phase 2Start 2022-06
  4. Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)RecruitingNCT05145361Study siteEarly phase 1Start 2022-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 19 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 3.8%.

Papers led
19
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 7720232024: 2220242025: 442025

3 hospitals in Xi'an for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06371040

    Age 18 years to 80 years (registered criteria)

    Led by Tangdu HospitalXi'an

  2. Recruiting
    Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
    Phase
    Phase 2
    Started
    2022-07
    Registry
    NCT05067348

    Age 18 years to 80 years (registered criteria)

    Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changsha, Chengdu, Shanghai, Tianjin, Xi'an

  3. Recruiting
    TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
    Phase
    Not given
    Started
    2019-11
    Registry
    NCT04182984

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  4. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

  5. Recruiting
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06447597

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an

  6. Recruiting
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04951622

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesThymus & thymectomyAntibodies & diagnosisBiologic & complement drugs
Departments in papersNeurologyPathology / laboratory medicine
Papers it led19
  1. Efficacy and Safety of Efgartigimod for Patients With Myasthenia Gravis in a Real-World Cohort of 77 Patients.2025CNS neuroscience & therapeuticsFree full text
  2. Association between antibody status and exacerbation in patients with myasthenia gravis who achieved minimal manifestation or better status.2025Journal of neurology
  3. Exploring the Roles of m6A-Modified circRNAs in Myasthenia Gravis Based on Multi-Omics Analysis.2025Molecular neurobiology
  4. Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study.2025Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeuticsFree full text
  5. Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis.2024CNS neuroscience & therapeuticsFree full text
  6. Factors associated with the disease family burden of caregivers of myasthenia gravis patients in northwestern China: A cross-sectional study.2024Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  7. Nomogram for predicting the risk of postoperative myasthenic crisis in patients with thymectomy.2023Annals of clinical and translational neurologyFree full text
  8. ASO Author Reflections: A Possible New Etiology of Thymoma-Associated Myasthenia Gravis-Human Parvovirus B19.2023Annals of surgical oncology
  9. Human Parvovirus B19 May Be a Risk Factor in Myasthenia Gravis with Thymoma.2023Annals of surgical oncologyFree full text
  10. Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.2023Frontiers in immunologyFree full text
  11. Knowledge mapping of global trends for myasthenia gravis development: A bibliometrics analysis.2023Frontiers in immunologyFree full text
  12. Landscape analysis of m6A modification regulators related biological functions and immune characteristics in myasthenia gravis.2023Journal of translational medicineFree full text
  13. Clinical characteristics and prognosis of very late-onset myasthenia gravis in China.2023Neuromuscular disorders : NMD
  14. Association of immunosuppression treatment with generalization among patients with ocular myasthenia gravis: A propensity score analysis.2022European journal of neurology
  15. Development and Validation of a Nomogram for Predicting Generalization in Patients With Ocular Myasthenia Gravis.2022Frontiers in immunologyFree full text
  16. Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.2022Journal of neurology
  17. Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study.2021BMC neurologyFree full text
  18. Thymectomy and Risk of Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study.2021Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeuticsFree full text
  19. Detection of IgM and IgG Antibodies to Human Parvovirus B19 in Sera of Patients with Thymoma-Associated Myasthenia Gravis.2021Viral immunology
All its trials on ClinicalTrials.gov, any status10
  1. Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia GravisRecruitingNCT05067348Lead sponsorPhase 2Start 2022-07
  2. TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world StudyRecruitingNCT04182984Lead sponsorStart 2019-11
  3. Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia GravisStatus unknownNCT05716035Lead sponsorPhase 2/Phase 3Start 2023-04
  4. Rituximab for the Treatment of New-onset AChR-Myasthenia GravisActive, not recruitingNCT07071246Lead sponsorN/AStart 2022-08
  5. The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal TumorStatus unknownNCT02317224Lead sponsorPhase 2Start 2014-08
  6. Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia GravisRecruitingNCT06371040Lead (inferred)Phase 1Start 2024-07
  7. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.RecruitingNCT06447597Study sitePhase 2/Phase 3Start 2024-07
  8. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Study siteStart 2024-02
  9. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07
  10. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisTerminatedNCT04963270Study sitePhase 3Start 2021-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Xi'an for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Xi'an for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Aortic stiffness evaluated by echocardiography in female patients with Takayasu's arteritis.2017Clinical and experimental rheumatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led no English-language PubMed papers on hepatic echinococcosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Xi'an for hepatic echinococcosis49 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Hepatic Hydatid Cyst Misdiagnosed as Simple Cyst: A Case Report.2020The American journal of case reports

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

12 hospitals in Xi'an for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Idiopathic pulmonary fibrosis microenvironment: Novel mechanisms and research directions.2025International immunopharmacology
Earlier papers (2016–2020)1
  1. Distal airway stem cells ameliorate bleomycin-induced pulmonary fibrosis in mice.2019Stem cell research & therapy
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Xi'an for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Xi'an for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Xi'an for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Expression and function of T-type α1H Ca(2)(+) channels in the rat model of Hirschsprung disease].2016Zhonghua er ke za zhi = Chinese journal of pediatrics

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

空军军医大学唐都医院

Tangdu Hospital

西安

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Air Force Medical University Tangdu Hospital; Tangdu Hospital of the Fourth Military Medical University; Tangdu Hospital of Air Force Military Medical University; Tangdu Hospital Fourth Military Medical University; Tangdu Hospital the Air Force Military Medical University; Tangdu Hospital of Air Force Medical University; Tangdu Hospital of the Fourth Military Medical; Tangdu hospital

Suggest a correctionDownload the data